US Food and Drug Administration gets it right

EDITOR-With reference to the news item by Burke, 1 the withholding of data provided by manufacturers for the use of the National Institute for Clinical Excellence (NICE) in reaching its decisions is in marked contrast to the policy followed by the Food and Drug Administration (FDA) in America.

Saved in:
Bibliographic Details
Published in:BMJ 2002-10, Vol.325 (7367), p.776-776
Main Author: Grove, Matthew L
Format: Article
Language:English
Subjects:
Cardiovascular Diseases - chemically induced
Chemical and Drug Induced Liver Injury
Cyclooxygenase 2
Drug Approval
Food security
Humans
Isoenzymes - adverse effects
Isoxazoles - adverse effects
Leflunomide
Letters
Medication administration
Membrane Proteins
Pharmaceutical industry
Prescription drugs
Prostaglandin-Endoperoxide Synthases - adverse effects
Records
United Kingdom
United States
United States Food and Drug Administration
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:EDITOR-With reference to the news item by Burke, 1 the withholding of data provided by manufacturers for the use of the National Institute for Clinical Excellence (NICE) in reaching its decisions is in marked contrast to the policy followed by the Food and Drug Administration (FDA) in America.
ISSN:0959-8138
0959-8146
1468-5833
1756-1833
DOI:10.1136/bmj.325.7367.776